Who are Collegium Pharmaceutical, Inc.'s main suppliers?

Collegium Pharmaceutical, Inc. (COLL) key suppliers include: HALO-PHARMACEUTICAL-INC, PATHEON, SHARP-PACKAGING-SOLUTIONS, UPM-PHARMACEUTICALS, Scilex Holding Company. View the full supplier network at chainsifter.com/chain/COLL.

Who are Collegium Pharmaceutical, Inc.'s major customers?

Collegium Pharmaceutical, Inc. (COLL) key customers include: Novartis AG, Novartis AG, Supernus Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated and 16 more. View the full customer network at chainsifter.com/chain/COLL.

What sector is Collegium Pharmaceutical, Inc. in?

Collegium Pharmaceutical, Inc. (COLL) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Collegium Pharmaceutical, Inc. Supplier List (COLL): 5 Verified Suppliers

5Suppliers

21Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Collegium Pharmaceutical, Inc. (COLL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

30Total relationships

2Distinct source URLs

8High confidence

0.721Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Collegium Pharmaceutical, Inc. Suppliers

Ticker	Name	Confidence	Evidence
HALO-PHARMACEUTICAL-INC	HALO-PHARMACEUTICAL-INC	92%	Nucynta IR is manufactured by Halo Pharmaceutical, Inc. in Whippany, New Jersey.
PATHEON	PATHEON	92%	Nucynta ER is currently manufactured by Patheon in Cincinnati, Ohio.
SHARP-PACKAGING-SOLUTIONS	SHARP-PACKAGING-SOLUTIONS	92%	Symproic is manufactured by UPM Pharmaceuticals in Bristol, Tennessee and packaged by Sharp Packaging Solutions in Allentown, Pennsylvania.
UPM-PHARMACEUTICALS	UPM-PHARMACEUTICALS	92%	Symproic is manufactured by UPM Pharmaceuticals in Bristol, Tennessee.
SCLX	Scilex Holding Company	72%	Reciprocal relationship from SCLX graph: Reciprocal relationship from COLL graph: Reciprocal relationship from SCLX graph: alth 110, LLC (“Cardinal Health 110”) and AmerisourceBergen Corporation (“Am…

Collegium Pharmaceutical, Inc. Customers

Ticker	Name	Confidence	Evidence
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from COLL graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from COLL graph: Reciprocal relationship from NVSE…
NVSEF	Novartis AG	72%	. At the same time, the Trump Administration has 61 Table of Contents endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on “Ens…
SUPN	Supernus Pharmaceuticals, Inc.	72%	Reciprocal relationship from SUPN graph: Reciprocal relationship from COLL graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from COLL graph: Reciprocal relationship from SUPN g…
SUPN	Supernus Pharmaceuticals, Inc.	72%	. At the same time, the Trump Administration has 61 Table of Contents endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on “Ens…
VRTX	Vertex Pharmaceuticals Incorporated	72%	. At the same time, the Trump Administration has 61 Table of Contents endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on “Ens…
VRTX	Vertex Pharmaceuticals Incorporated	72%	Reciprocal relationship from VRTX graph: Reciprocal relationship from COLL graph: . At the same time, the Trump Administration has 61 Table of Contents endorsed a federal moratorium on the enforcemen…
ACTAVIS-ENDO-MALLINCKRODT-PURDUE-TEVA-VERTEX-PHA	ACTAVIS-ENDO-MALLINCKRODT-PURDUE-TEVA-VERTEX-PHA	62%	. At the same time, the Trump Administration has 61 Table of Contents endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on “Ens…
ASRT	Assertio Holdings, Inc.	62%	Reciprocal relationship from ASRT graph: Reciprocal relationship from COLL graph: h 31, 2026, approximately $ 17,565 is due to the former Ironshore equity holders recorded as deferred business combin…
ASSERTIO-THERAPEUTICS-INC	ASSERTIO-THERAPEUTICS-INC	62%	h 31, 2026, approximately $ 17,565 is due to the former Ironshore equity holders recorded as deferred business combination consideration payable and $ 19,850 remains in escrow recorded as restricted …
BIODELIVERY-SCIENCES-INTERNATIONAL-INC	BIODELIVERY-SCIENCES-INTERNATIONAL-INC	62%	s 3,833 Total acquisition related expenses $ 24,329 F-25 BDSI Acquisition On March 22, 2022 (the “BDSI Acquisition Date”), the Company acquired BioDelivery Sciences International, Inc. (“BDSI…
BIOPHARMA-CREDIT-PLC	BIOPHARMA-CREDIT-PLC	62%	d payors are subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion fro…
BPCR-LIMITED	BPCR-LIMITED	62%	d payors are subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion fro…
CORIUM-LLC	CORIUM-LLC	62%	e time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets. (3) Provisions for trade allowances and chargebacks i…
CORIUM-THERAPEUTICS-HOLDINGS-LLC	CORIUM-THERAPEUTICS-HOLDINGS-LLC	62%	e time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets. (3) Provisions for trade allowances and chargebacks i…
J-J-INNOVATIVE-MEDICINES-SUPERNUS-PHARMACEUTICAL	J-J-INNOVATIVE-MEDICINES-SUPERNUS-PHARMACEUTICAL	62%	. At the same time, the Trump Administration has 61 Table of Contents endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on “Ens…
KNIGHT-THERAPEUTICS-INC	KNIGHT-THERAPEUTICS-INC	62%	any transaction price allocated to remaining performance obligations and any costs to obtain contracts with customers, including pre-contract costs and set up costs, were immaterial. Disaggregation…
NORTH-SOUND-PHARMACEUTICALS-INC	NORTH-SOUND-PHARMACEUTICALS-INC	62%	h 31, 2026, approximately $ 17,565 is due to the former Ironshore equity holders recorded as deferred business combination consideration payable and $ 19,850 remains in escrow recorded as restricted …
NUCYNTA-ER-AG	NUCYNTA-ER-AG	62%	e time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets. (3) Provisions for trade allowances and chargebacks i…
NUCYNTA-IR-AG	NUCYNTA-IR-AG	62%	e time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets. (3) Provisions for trade allowances and chargebacks i…
TRIS-PHARMA-NOVARTIS-AG-NOVEN-THERAPEUTICS-LLC	TRIS-PHARMA-NOVARTIS-AG-NOVEN-THERAPEUTICS-LLC	62%	. At the same time, the Trump Administration has 61 Table of Contents endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on “Ens…
UCB-SA-AYTU-BIOSCIENCE-INC-ADLON-THERAPEUTICS-IN	UCB-SA-AYTU-BIOSCIENCE-INC-ADLON-THERAPEUTICS-IN	62%	. At the same time, the Trump Administration has 61 Table of Contents endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on “Ens…

Collegium Pharmaceutical, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
COLL-DEBT-8791	Warrants outstanding: 2445	90%	xbrl warrant detail from xbrl 2018-12-31.
COLL-DEBT	Debt stack $14.2M	90%	Market cache reports total debt of $14.2M.
COLL-DEBT-8792	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2026-03-31.

Collegium Pharmaceutical, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. Ownership

Holder	Name	Confidence	Evidence
COLL-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 270 tracked holders.

Collegium Pharmaceutical, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
FDMT	4D Molecular Therapeutics, Inc.	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	2
AARD	Aardvark Therapeutics, Inc.	100.00	2
ABT	Abbott Laboratories	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
ELVN	Enliven Therapeutics, Inc.	100.00	2
A	Agilent Technologies, Inc.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
SLGL	Sol-Gel Technologies Ltd.	100.00	2
ASRT	Assertio Holdings, Inc.	100.00	1	['customer']
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
CRSP	CRISPR Therapeutics AG	100.00	2
DVLT	Datavault AI Inc.	100.00	2
HLNCF	Haleon plc	100.00	2

Collegium Pharmaceutical, Inc. Supply Chain